Metro Healthcare Berhad, (0329) Fair Value & Analysis
Healthcare · MY · Market cap 240M MYR
Fair value as of: Jul 17, 2026
From 24 valuation models · updated 24 days ago
Share price −10.6% over the past month.
A solid business, but screening 43% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (0.1500 MYR). The favourable scenario is already priced in.
- Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 17, 2026.
How to read this chart
60‑month range 0.1771 MYR – 0.6588 MYR · fair‑value band 0.0900 MYR – 0.1500 MYR · the 0.2100 MYR price screens above the 0.1200 MYR fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 17, 2026.
Analysis
Metro Healthcare Berhad, (0329) currently trades at 0.2100 MYR, while our model-based Fair Value estimate is 0.1200 MYR, implying the stock looks roughly 42.9% overvalued today. The Quality Score stands at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Metro Healthcare Berhad, generated revenue of 50.5M MYR at a net margin of 13.0%. Revenue grew 1.0% year over year. It earns a return on equity of 8.6%. The stock trades on a trailing P/E of 22.0. Fundamentals as of Jul 17, 2026
Our scenario range runs from 0.0900 MYR (bear case) to 0.1500 MYR (bull case); at 0.2100 MYR, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 12% below its 52-week high and 13% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at -43%, 0329 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: DCF Models (0.1500 MYR) versus Earnings-Based (0.0300 MYR). Highest evidence: Growth DCF (80).
Notify me when 0329 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 17, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 59 · Market factors (momentum, volatility) 51
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Metro Healthcare Berhad, together with its subsidiaries, provides hospital and related services in Malaysia. It offers inpatient; outpatient; and ambulatory care, including in vitro fertilization (IVF), intrauterine insemination (IUI), blastocyst culture, surgical sperm retrieval, preimplantation genetic screening (PGT), and assisted hatching services.
Full company description
Metro Healthcare Berhad, together with its subsidiaries, provides hospital and related services in Malaysia. It offers inpatient; outpatient; and ambulatory care, including in vitro fertilization (IVF), intrauterine insemination (IUI), blastocyst culture, surgical sperm retrieval, preimplantation genetic screening (PGT), and assisted hatching services. The company also provides fertility services, such as assisted reproductive technology and specialized fertility procedures; and obstetrics services that include pre-pregnancy screening and counselling, family planning counselling, antenatal checkup, and delivery services. In addition, it offers gynecology services, including hysterectomy, oophorectomy, colposcopy, hysteroscopy, laparoscopy, tubal ligation, dilation and curettage, and marsupialization; pediatrics services; diagnostic imaging services; and other healthcare services. Metro Healthcare Berhad was founded in 1989 and is based in Klang, Malaysia.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Metro Healthcare Berhad, reported revenue of 50.4M MYR in FY2025 versus 42.3M MYR in FY2021, a compound +4.5%/yr. Reported net income was 5.9M MYR in FY2025, compounding −11.2%/yr from FY2021.
0329 screens 43% overvalued. Compare with HCA Healthcare, Inc →
Peer Group
Medical Care Facilities · 261 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Care Facilities median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| HCA Healthcare, Inc HCA | $378.85 | $554.93 | +46% |
| Fresenius SE FRE | €41.73 | €32.15 | -23% |
| Dr. Sulaiman Al Habib Medical Services Group 4013 | 235.00 SAR | 112.37 SAR | -52% |
| IHH Healthcare Berhad, an investment holding company, Q0F | 2.58 SGD | 1.44 SGD | -44% |
| Tenet Healthcare Corporation THC | $194.91 | $338.05 | +73% |
| Rede D'Or São Luiz S.A RDOR3 | R$36.01 | R$47.31 | +31% |
| DaVita Inc DVA | $231.61 | $255.97 | +11% |
| Apollo Hospitals Enterprise Limited APOLLOHOSP | ₹8,955 | ₹2,955 | -67% |
| Fresenius Medical Care AG FMS | $24.68 | $45.60 | +85% |
| Aier Eye Hospital Group 300015 | ¥8.68 | ¥7.67 | -12% |
Compare Metro Healthcare Berhad, with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Metro Healthcare Berhad, (0329) overvalued or undervalued?
What is the fair value of 0329?
What is the quality score of 0329?
What is the revenue of Metro Healthcare Berhad, (0329)?
What is the net profit margin of 0329?
Does Metro Healthcare Berhad, pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Metro Healthcare Berhad, and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.